SLTM Antibody

What is SLTM and what are its primary biological functions?

SLTM (SAFB-like transcription modulator), also known as Modulator of estrogen-induced transcription, is a 1034 amino acid protein that localizes in the nucleus. It functions as both an epigenetic and transcriptional regulator with DNA binding, RNA binding, and protein binding capacities. When overexpressed, SLTM acts as a general inhibitor of transcription that can eventually lead to apoptosis . Recent research has identified SLTM as a novel HIV-1 silencing factor that suppresses HIV-1 expression at both the epigenetic and transcriptional levels .

The protein contains multiple functional domains that enable its various regulatory activities. While the calculated molecular weight of SLTM is 117 kDa, the modified protein typically appears at 135-140 kDa in experimental conditions, suggesting post-translational modifications . SLTM belongs to the SAFB family of chromatin regulators and has been shown to have a more potent effect in HIV-1 suppression compared to other members of this family .

How should researchers select an appropriate SLTM antibody for their specific experimental needs?

Selection of an appropriate SLTM antibody requires careful consideration of several factors:

• Experimental application compatibility: Different antibodies are optimized for specific applications. For example, antibody 17889-1-AP has been validated for Western Blot (WB), Immunohistochemistry (IHC), Immunofluorescence (IF)/ICC, and ELISA applications . When selecting an antibody, verify that it has been validated for your specific application with recommended dilution ranges.

• Species reactivity: Confirm that the antibody reacts with your species of interest. For instance, antibody 17889-1-AP shows reactivity with human, mouse, and rat samples , while A43957 shows reactivity specifically with human samples .

• Clone type and isotype: Consider whether a polyclonal or monoclonal antibody is more suitable for your research question. Polyclonal antibodies like A43957 (rabbit polyclonal) recognize multiple epitopes and may provide stronger signals but potentially less specificity than monoclonals .

• Validation data: Review the available validation data for the antibody in contexts similar to your experimental design. Examine Western blot images, IHC staining patterns, or other relevant validation data to ensure the antibody performs as expected in your system .

• Target region specificity: Some antibodies target specific regions of the protein (e.g., N-terminal vs. C-terminal), which may have different accessibility depending on your experimental conditions or protein interactions of interest .

What are the optimal protocols for using SLTM antibodies in Western blot applications?

Achieving optimal results with SLTM antibodies in Western blot applications requires attention to several methodological details:

Sample preparation:

• Use appropriate lysis buffers containing protease inhibitors to prevent protein degradation.

• Given that SLTM is a nuclear protein, nuclear extraction protocols may yield better results than whole-cell lysates.

• Include phosphatase inhibitors if investigating post-translational modifications of SLTM.

Gel selection and separation:

• Use 6-8% SDS-PAGE gels for optimal separation, as SLTM has a high molecular weight (observed at 135-140 kDa) .

• Load approximately 40μg of protein lysate per lane for optimal detection, as demonstrated in validation studies .

Transfer and antibody incubation:

• For large proteins like SLTM, longer transfer times or specialized transfer methods (e.g., wet transfer) may be necessary.

• When using antibody 17889-1-AP, a dilution range of 1:500-1:2000 is recommended .

• For antibody A43957, a dilution of 1:400 has been validated for Western blot applications .

• Overnight primary antibody incubation at 4°C can improve signal quality.

Detection and analysis:

• Use appropriate secondary antibodies at recommended dilutions (e.g., 1:8000 for HRP-conjugated anti-rabbit IgG when using A43957) .

• Be aware that SLTM may appear as multiple bands due to post-translational modifications or alternative splicing variants.

• Include positive control lysates (e.g., HeLa cells or mouse brain tissue) where SLTM expression has been confirmed .

How can researchers effectively apply SLTM antibodies in immunohistochemistry (IHC) and immunofluorescence (IF) studies?

For IHC applications:

• Antigen retrieval optimization:

  • For antibody 17889-1-AP, antigen retrieval with TE buffer pH 9.0 is suggested for optimal results.

  • Alternatively, citrate buffer pH 6.0 may be used, but comparative testing is recommended to determine which provides better staining for your specific tissue type .

• Antibody dilution:

  • Use SLTM antibody 17889-1-AP at a dilution range of 1:50-1:500 for IHC applications .

  • Always perform a dilution series to determine optimal concentration for your specific tissue type.

• Tissue-specific considerations:

  • Positive IHC staining has been documented in human skin cancer tissue with antibody 17889-1-AP .

  • For other tissue types, preliminary validation is recommended.

For IF/ICC applications:

• Cell fixation and permeabilization:

  • Standard paraformaldehyde fixation (4%) followed by Triton X-100 permeabilization is generally effective for nuclear proteins like SLTM.

  • Consider gentler permeabilization methods if examining specific nuclear substructures.

• Antibody dilution and incubation:

  • Use a dilution range of 1:50-1:500 for IF/ICC applications with antibody 17889-1-AP .

  • Positive IF/ICC staining has been documented in HepG2 cells .

• Nuclear counterstaining:

  • Include DAPI or other nuclear counterstains to confirm the expected nuclear localization of SLTM.

  • Consider co-staining with markers for specific nuclear substructures to define SLTM's precise subnuclear localization.

• Controls:

  • Include both positive controls (cell lines known to express SLTM, such as HepG2) and negative controls (antibody omission, pre-immune serum) to validate staining specificity .

How can SLTM antibodies be utilized to investigate chromatin accessibility and transcriptional regulation?

SLTM functions as both an epigenetic and transcriptional regulator, making SLTM antibodies valuable tools for investigating chromatin dynamics. Advanced research protocols include:

Chromatin Immunoprecipitation (ChIP) approaches:

• SLTM antibodies can be used to identify genomic regions bound by SLTM through ChIP-seq experiments.

• For ChIP applications, crosslinking optimization is crucial; standard 1% formaldehyde for 10 minutes may be appropriate, but optimization for SLTM binding is recommended.

• Sonication conditions should be optimized to generate DNA fragments of 200-500bp.

• A sequential ChIP approach (ChIP-reChIP) might reveal co-occupancy of SLTM with other transcription factors or chromatin modifiers.

Integration with ATAC-seq data:

• Research has shown that SLTM knockdown increases chromatin accessibility at specific regions, such as the HIV-1 provirus and integration sites .

• SLTM antibodies can be used in conjunction with ATAC-seq to correlate SLTM binding with changes in chromatin accessibility.

• When analyzing data, focus on both global changes and specific regions of interest where SLTM may exert its regulatory functions.

Transcriptional regulation studies:

• Given SLTM's role as a transcriptional modulator, combining ChIP data with RNA-seq following SLTM depletion or overexpression can provide insights into its direct transcriptional targets.

• Researchers can use SLTM antibodies in reporter assay systems to examine the direct effect of SLTM on promoter activity of genes of interest.

Experimental considerations for HIV-1 research:

• When investigating SLTM's role in HIV-1 silencing, researchers should design experiments that examine both the epigenetic (chromatin accessibility) and transcriptional aspects of regulation .

• SLTM antibodies can be used to track changes in SLTM binding to HIV-1 proviral DNA under different conditions (e.g., latency vs. activation).

What are the methodological approaches for investigating SLTM's role in HIV-1 latency and reactivation?

Recent research has identified SLTM as a novel HIV-1 silencing factor, making it a potential therapeutic target for HIV-1 reactivation strategies. Researchers interested in this area should consider the following methodological approaches:

CRISPR inhibition (CRISPRi) system:

• CRISPRi targeting SLTM has been shown to significantly increase HIV-1-driven GFP expression in HIV-1-infected Jurkat T cell clones by 1.9- to 4.2-fold .

• When implementing CRISPRi, design multiple sgRNAs targeting SLTM and select those with highest knockdown efficiency.

• Validate SLTM knockdown using qRT-PCR, as commercial Western blot antibodies may have limitations in some experimental systems .

siRNA knockdown approaches:

• siRNA targeting SLTM has been successfully used to reduce SLTM expression in CD4+ T cells from ART-treated, virally suppressed HIV-1-infected individuals .

• Optimize transfection protocols for primary T cells to ensure efficient knockdown with minimal cellular toxicity.

• Use appropriate controls, including non-targeting siRNAs, to account for non-specific effects.

Chromatin accessibility analysis:

• ATAC-seq can be used to assess changes in chromatin accessibility at the HIV-1 provirus and integration sites following SLTM manipulation .

• Include appropriate controls such as housekeeping genes (e.g., POLR2A) to demonstrate specificity of chromatin changes .

Ex vivo reactivation assays:

• When working with samples from HIV-1-infected individuals, limiting dilution culture can be used to quantify the frequency of cells harboring inducible HIV-1 .

• SLTM knockdown has been shown to reduce the frequency of HIV-1-infected cells harboring inducible HIV-1 by 62.2% (0.56/10^6 versus 1.48/10^6 CD4+ T cells) .

Data analysis considerations:

• When analyzing the effect of SLTM manipulation on HIV-1 expression, consider both the magnitude of HIV-1 reactivation and the proportion of cells showing reactivation.

• For chromatin studies, analyze changes at multiple regions of the HIV-1 provirus, as SLTM knockdown has been shown to particularly affect the U3 region of the HIV-1 LTR promoter and 3′ genome .

What are common challenges in Western blot detection of SLTM and how can they be addressed?

Researchers frequently encounter specific challenges when detecting SLTM via Western blot:

High molecular weight detection issues:

• SLTM has an observed molecular weight of 135-140 kDa despite a calculated weight of 117 kDa, suggesting post-translational modifications .

• For high molecular weight proteins like SLTM:

  • Use lower percentage gels (6-8% SDS-PAGE) for better resolution .

  • Employ longer transfer times or specialized transfer methods for large proteins.

  • Consider using PVDF membranes instead of nitrocellulose for better protein retention.

Multiple band patterns:

• SLTM may appear as multiple bands due to post-translational modifications or alternative splicing.

• Isoform-specific detection may require antibodies targeting specific regions of the protein.

• Use appropriate positive controls (e.g., HeLa cells or mouse brain tissue) to help distinguish specific from non-specific bands .

Low signal issues:

• If experiencing low signal:

  • Increase protein loading (40μg per lane has been validated) .

  • Optimize primary antibody concentration (try a dilution series).

  • Extend primary antibody incubation time (overnight at 4°C).

  • Consider enhanced detection systems for low-abundance proteins.

Specificity verification:

• To confirm antibody specificity:

  • Include SLTM-depleted samples (via siRNA or CRISPR) as negative controls.

  • Compare patterns across multiple validated SLTM antibodies targeting different epitopes.

  • Consider peptide competition assays to demonstrate specificity of binding.

Special considerations for research contexts:

• Note that some commercially available Western blot antibodies for SLTM may have limitations in certain experimental systems. In some cases, RNA qRT-PCR may be a more reliable method to measure SLTM expression levels .

How should researchers address contradictory or unexpected findings when studying SLTM function using antibody-based methods?

When researchers encounter contradictory or unexpected results in SLTM studies, several methodological approaches can help resolve discrepancies:

Antibody validation strategies:

• Validate antibody specificity through multiple approaches:

  • Compare results with at least two different antibodies targeting distinct epitopes of SLTM.

  • Implement genetic approaches (siRNA, shRNA, or CRISPR/Cas9) to create SLTM-depleted controls.

  • Perform rescue experiments by re-expressing SLTM in knockout models to confirm phenotype specificity.

Resolution of discrepant molecular weight observations:

• If observed molecular weights differ from expected (135-140 kDa):

  • Investigate potential post-translational modifications using phosphatase treatments or specific PTM antibodies.

  • Consider the possibility of alternative splicing variants; design PCR primers to detect potential isoforms.

  • Examine sample preparation methods that might affect protein migration patterns.

Contextual differences in SLTM function:

• SLTM functions may vary across different cellular contexts:

  • Compare results across multiple cell types when possible.

  • Consider the influence of cell cycle stage, differentiation status, or stress conditions on SLTM function and localization.

  • Examine potential interactions with other proteins that might modulate SLTM activity in context-specific ways.

Integration of multiple methodological approaches:

Handling contradictory published data:

• When findings contradict published literature:

  • Carefully examine methodological differences that might explain discrepancies.

  • Consider cell type-specific or context-dependent effects.

  • Directly contact authors of contradictory studies to discuss technical details that might not be apparent from published methods.

How can SLTM antibodies be integrated into advanced techniques for studying protein-protein and protein-nucleic acid interactions?

SLTM's multiple functional domains enable diverse molecular interactions that can be studied using advanced antibody-based techniques:

Co-Immunoprecipitation (Co-IP) approaches:

• SLTM antibodies can be used for Co-IP to identify protein interaction partners in different cellular contexts.

• When designing Co-IP experiments:

  • Optimize lysis conditions to preserve native protein interactions.

  • Consider crosslinking approaches for transient interactions.

  • Use both N-terminal and C-terminal targeting antibodies to account for potential epitope masking in protein complexes.

Chromatin Immunoprecipitation (ChIP) variations:

• Beyond standard ChIP, consider:

  • ChIP-seq to map genome-wide binding patterns of SLTM.

  • CUT&RUN or CUT&Tag for higher resolution and lower background than traditional ChIP.

  • HiChIP to connect SLTM binding with 3D chromatin organization.

RNA-protein interaction studies:

• Given SLTM's RNA-binding capacity, consider:

  • RNA Immunoprecipitation (RIP) to identify RNA targets.

  • CLIP-seq (Cross-linking immunoprecipitation) for higher-resolution mapping of RNA-binding sites.

  • RNA-protein interaction maps in different cellular contexts, particularly during HIV-1 infection and latency.

Proximity labeling approaches:

• Combine SLTM antibodies with emerging proximity labeling techniques:

  • BioID or TurboID fusion proteins to identify proteins in close proximity to SLTM.

  • APEX2-based proximity labeling for temporal resolution of SLTM interaction networks.

  • Split-BioID to study context-specific interactions between SLTM and suspected partners.

Super-resolution microscopy applications:

• SLTM antibodies can be adapted for advanced imaging:

  • STORM or PALM imaging to define SLTM's subnuclear localization with nanometer precision.

  • Live-cell super-resolution to capture dynamic behaviors.

  • Multi-color imaging to study co-localization with other nuclear factors.

What considerations should guide experimental design when studying SLTM's role in HIV-1 latency reversal for therapeutic applications?

The discovery of SLTM as a potential therapeutic target for HIV-1 reactivation presents exciting research opportunities that require careful experimental design:

Translation from cell lines to primary cells:

• While initial findings in Jurkat T cell lines showed SLTM knockdown increased HIV-1 expression by 1.9- to 4.2-fold , primary cell studies require:

  • Optimization of gene knockdown methods for primary CD4+ T cells.

  • Consideration of donor-to-donor variability in SLTM expression and function.

  • Establishment of appropriate ex vivo models that recapitulate key aspects of in vivo latency.

Combination approaches for latency reversal:

• Design experiments to evaluate SLTM inhibition in combination with:

  • Established latency-reversing agents (LRAs) such as HDAC inhibitors.

  • Other epigenetic modulators targeting different mechanisms of HIV-1 silencing.

  • Immunomodulatory compounds that might enhance clearance of reactivated cells.

Specificity and safety assessment:

• When evaluating SLTM as a therapeutic target:

  • Examine effects on global gene expression beyond HIV-1.

  • Assess potential off-target effects on cellular pathways.

  • Evaluate effects on T cell function, survival, and immune responses.

Quantitative assessment of HIV-1 reservoir reduction:

• Design rigorous quantification approaches:

  • Limiting dilution assays to quantify changes in the inducible reservoir .

  • Droplet digital PCR for precise quantification of intact proviruses.

  • Viral outgrowth assays to assess replication-competent virus.

Mechanistic studies:

• Investigate the molecular mechanisms underlying SLTM's effects:

  • ATAC-seq to map changes in chromatin accessibility at HIV-1 integration sites .

  • ChIP-seq to identify direct binding of SLTM to HIV-1 proviral DNA.

  • Transcriptomic analyses to understand broader effects of SLTM inhibition.

What validation strategies should researchers employ to ensure SLTM antibody specificity and reproducibility?

Ensuring antibody specificity and experimental reproducibility is crucial for research integrity:

Multiple antibody validation approaches:

Application-specific validation:

• For each experimental application (WB, IHC, IF, ChIP):

  • Determine optimal antibody concentrations (e.g., 1:500-1:2000 for WB using 17889-1-AP) .

  • Validate using appropriate positive controls (e.g., HeLa cells, mouse brain tissue) .

  • Include appropriate negative controls (antibody omission, isotype controls).

Batch-to-batch consistency:

• When receiving new antibody lots:

  • Compare performance with previous lots using standardized samples.

  • Document lot-specific optimal conditions.

  • Consider creating a reference sample set for long-term projects.

Reporting standards:

• When publishing:

  • Report complete antibody information (supplier, catalog number, lot, dilution).

  • Include validation data or cite previous validation.

  • Describe all experimental conditions in detail to enable reproduction.

How can researchers address the challenges of antibody cross-reactivity and specificity in complex experimental systems?

Cross-reactivity and specificity concerns require systematic approaches to ensure reliable results:

Cross-reactivity assessment strategies:

• Employ western blot analysis to evaluate potential cross-reactivity with:

  • Related family members (other SAFB family proteins).

  • Proteins of similar molecular weight.

  • Proteins expressed in the same subcellular compartment.

Specificity confirmation in tissue sections:

• For IHC/IF applications:

  • Use antigen retrieval optimization (e.g., TE buffer pH 9.0 for 17889-1-AP) .

  • Include absorption controls with immunizing peptide.

  • Compare staining patterns with published data and expected subcellular localization.

  • Consider multiplex staining with markers of subcellular compartments.

Advanced specificity testing:

• Implement more rigorous approaches:

  • Mass spectrometry analysis of immunoprecipitated samples.

  • Comparison of immunostaining with mRNA expression (ISH).

  • Correlation of protein levels detected by antibody with mRNA levels across multiple samples.

Addressing technical limitations:

• Note that in some experimental systems, commercial Western blot antibodies may have limitations, as observed in certain HIV-1 studies where RNA qRT-PCR was used as an alternative to measure SLTM expression .

• Consider alternative detection methods when appropriate, such as:

  • Tagged protein expression systems.

  • CRISPR knock-in of endogenous tags.

  • Proximity labeling approaches.